Thrivent Financial for Lutherans Sells 660,825 Shares of Novo Nordisk A/S (NYSE:NVO)

Thrivent Financial for Lutherans decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 83.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 129,600 shares of the company's stock after selling 660,825 shares during the period. Thrivent Financial for Lutherans' holdings in Novo Nordisk A/S were worth $15,432,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC grew its position in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock worth $26,000 after purchasing an additional 120 shares during the period. Halpern Financial Inc. boosted its stake in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company's stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Finally, Abound Wealth Management boosted its stake in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company's stock worth $31,000 after acquiring an additional 157 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Finally, BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Buy" and a consensus price target of $144.50.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $2.50 during trading hours on Thursday, reaching $102.77. 5,361,193 shares of the stock traded hands, compared to its average volume of 4,502,149. The company has a market cap of $461.18 billion, a P/E ratio of 33.26, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company's 50-day moving average price is $116.12 and its two-hundred day moving average price is $128.92.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.